Failure of the Phase 2 study (protocol FB401-01) to meet its endpoint.

The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for up to 48 additional weeks and subjects will be evaluated for safety.

Inclusion Criteria:

• Participated in Protocol FB401-01, completed through Week 20 visit and able to directly enroll into this (FB401-02) study
• Refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor

Exclusion Criteria:

• Subject experienced a serious adverse event or severe adverse event attributable to study drug in Protocol FB401-01
• Severe concomitant illness that, in the Investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological
• Pregnant (or planning to become pregnant during the period of the study) or lactating females